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Abstract
Background: With the exception of some live vaccines, e.g. BCG, subunit vaccines formulated with ‘‘classical’’ adjuvants do
not induce similar responses in neonates as in adults. The usual neonatal profile is characterized by lower levels of TH1-
associated biomarkers. This has hampered the development of new neonatal vaccines for diseases that require early
protection. Tuberculosis is one of the major targets for neonatal immunization. In this study, we assessed the
immunogenicity of a novel candidate vaccine comprising a mycobacterial fusion protein, Ag85B-ESAT-6, in a neonatal
murine immunization model.
Methods/Findings: The Ag85B-ESAT-6 fusion protein was formulated either with a classical alum based adjuvant or with the
novel IC31H adjuvant. Following neonatal or adult immunization, 3 parameters were studied in vivo: (1) CD4
+ T cell
responses, (2) vaccine targeting/activation of dendritic cells (DC) and (3) protection in a surrogate mycobacterial challenge
model. Conversely to Alum, IC31H induced in both age groups strong Th1 and Th17 responses, characterized by
multifunctional T cells expressing IL-2 and TNF-a with or without IFN-c. In the draining lymph nodes, a similarly small
number of DC contained the adjuvant and/or the antigen following neonatal or adult immunization. Expression of CD40,
CD80, CD86 and IL-12p40 production was focused on the minute adjuvant-bearing DC population. Again, DC targeting/
activation was similar in adults and neonates. These DC/T cell responses resulted in an equivalent reduction of bacterial
growth following infection with M. bovis BCG, whereas no protection was observed when Alum was used as adjuvant.
Conclusion: Neonatal immunization with the IC31H- adjuvanted Ag85B-ESAT-6 subunit vaccine elicited adult-like
multifunctional protective anti-mycobacterial T cell responses through the induction of an adult pattern of in vivo DC
activation.
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Introduction
Tuberculosis (TB) continues to be a global disease burden
despite the widespread use of Bacillus Calmette Guerin (BCG)
immunization (www.who.int/mediacentre/factsheets/fs104/en).
Considerable efforts are aiming at the development of novel, safer
and more efficacious vaccines against tuberculosis [1,2]. A major
limitation towards the achievement of this goal is a lack of reliable
biomarkers of protective immunity against M. tuberculosis (Mtb).
Both CD4
+ and CD8
+ T cells may contribute to protection, a
central role for CD4
+ T cells being suggested by the disease
patterns in HIV-1 infected patients [3]. A critical function for anti-
mycobacterial effectors is to produce type 1 cytokines, as
highlighted by the severity of mycobacterial infections in children
with genetic mutations in the IL-12/IFN-c axis [4,5] or by the
high rate of Mtb reactivation and disease progression in patients
treated with TNF-a inhibitors [6]. Multifunctional T cells
concomitantly expressing several cytokines are thought to play a
crucial role in protection against various infections [7,8], and this
may also apply to tuberculosis.
Exposure to Mtb may occur very early in life and infections with
Mtb are frequently severe in infants and young children whose
immature immune system fails to limit bacterial spread [9].
Therefore immunization strategies against TB should include the
neonatal induction of potent anti-mycobacterial responses and to
prove safety of such neonatal strategies. Currently, BCG
vaccination is quite effective (approximately 80%) in human
infants [10]. It may induce adult-like IFN-c responses [11,12],
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3683probably as a result of potent DC activation as BCG enhanced
responses to a simultaneously administered hepatitis B vaccine
[13]. However, although it was recently demonstrated that BCG
elicits infant T cells with complex cytokine and phenotypic profiles
[14,15], no specific pattern distinguishing BCG-protected from
non-protected children has yet emerged. Major BCG-related
issues are (1) a limited persistence of the protective efficacy and
failure to protect against pulmonary disease, (2) negative
interference by previous exposure to environmental mycobacteria,
(3) safety concerns in HIV-1 infected children. This emphasizes
the need for safer and more efficacious infant TB vaccines.
Novel TB vaccines have been recently developed and a few have
already entered into clinical trials which will define their safety and
immunogenicity in naı ¨ve or previously exposed adults [1]. At this
stage, predicting which of the novel candidates might also prove
immunogenic in human infants will be largely empirical and lead to
difficult ‘‘go-no go’’ decisions. The general objective of our studies is
to generate preclinical evidence supporting the decision process for
further vaccine development in children and infants. There is ample
evidence that mice may not be reliably used to predict human
vaccine efficacy. However, the main stages of immune maturation
are sufficiently well conserved between humans and mice for
specific neonatalanimalmodels to accurately predictwhetherinfant
B and T cell response patterns will compare to those elicited in
immunologically mature hosts [16–19]. It is of interest that both
human and murine neonates exhibit limited IFN-c expression
capacity and limited Th1 responses that likely reflect differences in
neonatal and adult DC activation profiles [20].Aluminiumsalts,the
only adjuvants currently licensed for use in infants, exacerbate the
Th2-like profile of responses [21–23]. Remarkably, these neonatal
limitations can be overcome by some specific vaccines and/or
through appropriate DC activation signals [11,24,25]. It appears of
importance a priori that new TB vaccines that would be considered
for use in early life should be capable of inducing in vivo a similar
pattern of T cell and DC responses in both immunologically mature
and immature hosts.
Here, we assessed the T cell and DC in vivo activation patterns
elicited by a fusion protein of two major tuberculosis antigens
(Ag85B and ESAT-6) formulated in a novel adjuvant, IC31H
(registered CTM and US trademark and is covered inter alia by
international patent applications PCT/EP01/12041 and PCT/
EP01/06433, both are pending or granted in several countries).
The IC31H adjuvant contains a KLK peptide and a TLR-9-
triggering non-CpG oligonucleotide (ODN1a) [26,27] and confers
protective efficacy in challenge models of murine tuberculosis
[28,29]. IC31H-adjuvanted Ag85B-ESAT-6 was recently shown to
induce potent responses in a clinical trial [30]. We show here that
this vaccine candidate elicits the exact same pattern of multifunc-
tional CD4
+ T cells and of focused in vivo DC activation in
neonates as in adults.
Results
Induction of adult-like multifunctional neonatal CD4
+ T
cells
C57Bl/6 mice were primed at 1 week of age (i.e. at the stage of
immune maturation that most closely reflect that of human
neonates [16] with Ag85B-ESAT-6 (5 mg) formulated in IC31H or
aluminum hydroxide (Alum, control) via the subcutaneous (s.c.)
route. Mice were boosted 3 weeks later, unless indicated
otherwise. Neonatal weight gain, a sensitive method of monitoring
neonatal reactogenicity, was normal in each group and the
incidence of local reactions (inflammatory nodules) was similar to
that of adult mice (data not shown).
Immunization with Ag85B-ESAT-6 in Alum elicited signifi-
cantly weaker IFN-c and stronger IL-5 responses in mice primed
as neonates than as adults, a Th2-preferential pattern character-
istic of neonatal vaccine responses (Figure 1). In contrast, Ag85B-
ESAT-6 in IC31H elicited a mirror pattern with similarly high
IFN-c responses and modest IL-5 responses in both age groups.
This induction of adult-like neonatal responses was confirmed by
assessing the cytokine frequency and production of IFN-c IL-2,
TNF-a and IL-17 (Table 1). Most Ag-specific CD4
+ T cells
produced TNF-a and/or IL-2 in both age groups. IFN-c
producing cells were fewer, but present at similar proportions in
neonates and adults (Table 1). As previously observed in adult
mice [29], only CD4
+ T cell responses to Ag85B-ESAT-6 were
elicited: Ag-specific CD8
+ T cells were not detected by flow
cytometry nor was there a decrease in IFN-c production when
CD8
+ T cells were blocked during in vitro culture (data not shown).
Remarkably, adult-like Th1 responses were already elicited after a
single neonatal immunization in IC31H (Table 1). Adding a 3
rd
Figure 1. Unlike alum, the IC31H adjuvant induces adult-like
Th1 cell responses in neonates. Three weeks after the second
immunization, splenocytes from neonatal and adult immunized mice
were restimulated with antigen for 3 days. The production of IFN-c (A)
and IL-5 (B) is represented by the mean and SD of groups of at least 6
individual mice, and is representative of 3 independent experiments. *,
p,0.05 signifies differences between neonates and adult mice.
doi:10.1371/journal.pone.0003683.g001
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nd dose did not further increase
Ag85B-ESAT-6 specific CD4
+ T cell responses (not shown).
To further delineate the functionality of Ag85B-ESAT-6 specific
CD4
+ T cells, the co-production of IFN-c, TNF-a and IL-2 was
assessed by FACS intracellular staining (ICS). Six weeks after
boosting, IFN-c, TNF-a and IL-2 were produced by CD44
hi
activated/memory CD4
+ T cells (Figure 2A). Combination gating
was used to determine the cytokine production of single T cells in
individual mice (Figure 2B). Although the distribution of multi-
cytokine production varied as expected among individual mice,
the same pattern was observed whether mice were immunized as
adults or neonates (Figure 2C). Most cytokine
+ T cells produced
TNF-a/IL-2, often with IFN-c. Remarkably, the same cytokine
production pattern was observed in mice primed as neonates.
Thus, neonatal immunization with IC31H-adjuvanted Ag85B-
ESAT-6 was well tolerated and elicited adult-like multifunctional
CD4
+ T cell responses that markedly differ from the Th2-biased
neonatal pattern induced with the Alum adjuvant.
In vivo activation of neonatal and adult vaccine-targeted
dendritic cells
The 2
nd stage of our vaccine candidate evaluation includes a
detailed assessment of in vivo DC activation patterns. Using
fluorochrome-labeled formulations to track antigen (Ag)
+ and/or
adjuvant (Adj)
+ DC in draining lymph nodes (LN), we previously
reported that IC31H induces in adult mice an exquisite DC
activation that may be detected in the draining LN 24 h after
priming [31]. Despite their very small size, the draining LN of 1-
week-old mice were harvested 24 h after a single injection of
IC31H-adjuvanted Ag85B-ESAT-6. Most Adj
+ LN cells (,85%)
were DCs in adult LN (Figure 3A). This proportion was slightly
lower in 1-week-old mice, indicating some uptake by non-DC
populations. Among neonatal Adj
+ DCs, only a minority (,25%)
were also Ag
+ DC, as observed in adults (Figure 3B). Remarkably,
the number of Adj
+ and of Ag
+Adj
+ DC was similar in neonates
and in adults (Figure 3C), despite the difference of LN cellularity
(not shown). Assessing the surface expression of the CD40, CD80
and CD86 co-stimulation molecules indicated that IC31H only
activated Adj
+ DCs (Figure 4A) in both age groups. Remarkably,
DC activation was phenotypically similar in neonates and adults.
This was confirmed by the quantification of IL-12p40 expression,
only visualized in Adj
+ DC and observed at the same level in
neonates as in adults (Figure 4B). Thus, a similar exquisite in vivo
DC activation pattern was elicited by IC31H-adjuvanted Ag85B-
ESAT-6 both in adults and neonates.
As Ag85B-ESAT-6 in Alum did not elicit the same pattern of T
cell responses in neonates and in adults (Figure 1), potential
differences in the pattern of in vivo DC activation elicited by
immunization in Alum were investigated. As aluminium salts
could not be fluorescently labeled, LN cells harvested 24 h after
immunization were gated on Ag
+ DC. Remarkably, the number of
Ag
+ DC was similar in adults and neonates (Figure 5A), and
similar (,500 cells) to that elicited by IC31H (Figure 3). In adults,
a slightly higher expression of CD86, but not of CD40, was
observed on Ag
+ DC (Figure 5B). This partial activation of adult
Ag+ DCs did not translate into any increase of IL-12 p40
expression and was not observed in neonates (Figure 5B and data
not shown) despite the efficient targeting of neonatal DC.
Protective efficacy of novel vaccines against
mycobacterial infection
The 3
rd stage of our TB vaccine evaluation includes a
mycobacterial challenge model. Six weeks after the second
immunization with IC31H-adjuvanted Ag85B-ESAT-6, mice were
challenged i.v. with Mycobacterium bovis BCG. In accordance with
CD4
+ T cell responses, Ag85B-ESAT-6 did not confer any protective
efficacy when formulated in Alum, as the number of CFU in spleen
and lungs was as high as in control mice regardless of age at
immunization (Figure 6A,B). In contrast, significantly lower bacterial
counts were recovered from mice immunized with IC31H-adjuvanted
Ag85B-ESAT-6 either as adults or as neonates (Figure 6A, B).
Discussion
Conventional vaccine formulations elicit Th2-biased CD4
+ T
cell responses when used in early life and specific requirements
have to be met for vaccine formulations and/or adjuvants to
successfully elicit adult-like Th1 neonatal responses [32,33]. We
show here that a novel subunit vaccine currently in clinical
development against TB meets all the predefined preclinical
criteria predicting adult patterns of human immune responses after
administration in early life.
When mice were immunized with Ag85B-ESAT-6/IC31H,a n
extensive evaluation of CD4
+ T cell responses failed to identify any
Table 1. Ag85B-ESAT-6-specific T cell response following immunization with antigen- IC31H formulation.
In vitro stimulation
a Ex vivo intracellular cytokine staining
b (% of CD44
+ CD4
+ T cells)
Neonates Adult p value
c Neonates Adult p value
2 doses
IFN-c 2926153 213694 ISC/10
6 splenocytes NS 3.863.2 2.960.3 NS
IL-2 4.961.3 1.260.5 U/ml NS 6.865.6 5.160.6 NS
TNF-a 1.060.2 0.760.2 ng/ml NS 7.365.7 5.760.7 NS
IL-17 7.562.4 9.565.7 ng/ml NS ND
d ND
1 dose
IFN-c 17.861.3 6.560.6 ng/ml NS ND ND
IL-5 0.660.2 0.561.0 ng/ml NS ND ND
aIFN-c secreting cells (ISC)/10
6 splenocytes were determined after 48 hr and IL-2 (bioassay), TNF-a, IL-17, IFN-c and IL-5 (ELISA) after 72 hr of culture.
bFollowing 6 hr culture with antigen and co-stimulation (CD28/CD49d), percent of cytokine-producing cells determined by flow cytometry.
cNS: p.0.05.
dND: not done.
doi:10.1371/journal.pone.0003683.t001
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and adults. This was demonstrated for a large panel of Th1
cytokines including TNF-a, IFN-c, IL-2 and IL-17, which were
assessed in the supernatant of in vitro restimulated T cells and/or
through the number of cytokine-producing cells. An adult-like
pattern of responses was also observed following the quantification
of multifunctional CD4
+ T cells secreting 2–3 distinct Th1
cytokines. Whether multifunctional T cells do play a direct role in
Figure 2. Ag85B-ESAT-6/IC31H stimulates production of multifunctional T cells in neonates and adults. The expression of IFN-c, IL-2 and
TNF-a was determined by FACS ICS on splenocytes from neonatal and adult immunized mice (A) CD4
+ T cells, from neonates immunize with Ag/
IC31H or control, were stimulated with antigen or media. Cytokine production was only detected in cells from Ag/IC31H-immunized mice stimulated
with antigen. The same expression pattern was observed with splenocytes from adult immunized mice (not shown) (B) Gating combination to
determine concomitant cytokine expression. Representative gating of CD4
+ CD44
+ T cells from Ag/IC31H-immunized mice stimulated with antigen:
IFN-c
+ and IFN-c
2 populations were plotted as IL-2 versus TNF-a. (C) The concurrent expression of IFN-c, IL-2 and TNF-a is represented as pie graphs
of cytokine expression by CD4
+ CD44
+ T cells of individual mice, and is representative of 2 independent experiments.
doi:10.1371/journal.pone.0003683.g002
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patterns are conserved even when immunization takes place in
immature neonatal hosts strongly suggests that Ag85B-ESAT-6/
IC31H mediated signals fully overcome the limitations of innate
and adaptive neonatal immunity. This achievement may not be
accounted for by ongoing immune maturation, as an adult pattern
of CD4
+ T cell responses was already observed after a single
immunization of 1-week-old mice. It may also not be ascribed to
immunogenic properties of Ag85B-ESAT-6, as its use with Alum
generated markedly biased Th2 neonatal responses. Thus, the
induction of multifunctional CD4
+ Th1 cells both in immature
and mature hosts reflects the potent Th1-driving capacity of
IC31H. Yet, this was not associated with excess inflammatory
reactions – meeting another important criterion for considering
the use of vaccine candidates in neonates. In contrast to the
neonatal use of a number of other immunomodulators or novel
adjuvants [18,21,32,34] (and not shown), we observed neither
systemic nor local reactogenicity following s.c. injection of Ag85B-
ESAT-6/IC31H in neonates.
Immune responses elicited by Ag85B-ESAT-6/IC31H conferred
significant protection against a non-lethal mycobacterial challenge:
following BCG infection, mycobacterial counts were significantly
reduced in the lungs and spleens of mice immunized with Ag85B-
ESAT-6/IC31H, as compared to the use of Alum. This reduction
was similar regardless of age at immunization, indicating again no
influence of the stage of immune maturation on vaccine-induced
protection. Acknowledging the fact that a non-lethal BCG
challenge is only a proxy of Mtb infection, neonates were primed
with Ag85B-ESAT-6/IC31H, boosted and submitted to an aerosol
Mtb challenge as described [29]. Logistic limitations only allowed
us to run a single experiment, which concluded to a significant
reduction of bacterial counts in immunized compared to naı ¨ve
Figure 3. Exquisite targeting of Ag85B-ESAT-6 in neonatal and adult DC of the draining LN. Twenty-four hours after immunization, (A)
the percent of IC31H-Cy5
+ CD11c
+ cells compared to all cells-bearing the adjuvant in the draining LN was determined. In a representative dot plot,
the percent of cells in quadrants is shown (B) The percent of Ag85-ESAT-6
+ IC31H
+ DC amongst all IC31H
+ DC was determined. In a representative
histogram, presence of Ag85-ESAT-6-FITC in IC31H
+ DC (thick line) was calculated using total DC as the control histogram (dotted line). (C) The
number of IC31H
+ and Ag85-ESAT-6
+ IC31H
+ DC in the draining LN was calculated. The data are expressed as mean and SD of groups of at least 5
individual mice, and is representative of 3 independent experiments. *, p,0.05 signifies differences between neonates and adult mice.
doi:10.1371/journal.pone.0003683.g003
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to be confirmed in the future, it adds further evidence to our
conclusion that the use of IC31H as an adjuvant in early life
vaccines does overcome neonatal immune limitations.
The main stage of our preclinical neonatal vaccine evaluation
platform relies on the assessment of in vivo DC activation. Indeed,
the unavailability of validated surrogates of protective responses
frequently limits the predictive capacity of preclinical models:
immunological studies would not include yet unidentified
cytokines/patterns of responses, whereas protective mechanisms
may differ across species. Being at the intersection of innate and
adaptive immunity, DC targeting and activation is a most sensitive
marker of differences in responses to pathogen-associated
molecular patterns (PAMPS)-mediated signaling [35,36]. In this
report, Ag85B-ESAT-6 was used with Alum and IC31H, two
adjuvants whose biochemical/signaling properties markedly differ.
Remarkably, only a small but similar number of Ag
+ LN DC were
identified in the draining LN 24 h after the injection of IC31H-o r
Alum-adjuvanted Ag85B-ESAT-6. Factors that control DC
antigen uptake/migration were thus not modulated by the use of
two adjuvants markedly differing in their Th1 (IC31H) or Th2
(Alum) properties.
Both innate and adaptive immunity markedly differ in early
life [18,33]. Consequently, both human and murine neonatal
DC differ from their adult counterparts in their response
capacity to different PAMPS [20,37–39]. The direct assessment
of vaccine-targeted neonatal DC in the minute draining LN of
8-day-old mice was technically challenging. However, this was
required to define the influence of immune maturation on the
type of vaccine-targeted cells, their numbers and their state of
activation following immunization. The observation of a similar
number of Ag
+ LN DC in neonates and in adults indicates that
DC antigen uptake/migration capacities are already fully
functional at 7 days of age, even when adjuvants as weak as
Alum are used. These similarities are quite remarkable given the
differences in the numbers of DC present in neonatal and adult
mice [37,38]. They do not result from a more mature LN
microenvironment [18] as a similar distribution of vaccine-
targeted cells was observed in the spleen following i.p.
immunization (not shown). Thus, neither the excess Th2
responses of neonates injected with Alum or the strong Th1
responses following the injection of IC31H result from differences
in the numbers of Ag
+ DC.
The neonatal use of IC31H elicited not only an adult-like
number of Ag
+ cells but also their adult-like activation pattern.
This activation was restricted to Adj
+ cells, whether DC were also
Ag
+ or not, as previously observed in adults [31]. Both phenotypic
maturation and IL-12p40 expression were adult-like, indicating
that neonatal DCs responded to IC31H-generated signals within
24 h of immunization. As IC31H is known to signal through TLR-
9, this observation is in accordance with reports by us [40,41] and
others [37,39,42,43] that TLR-9 signals are readily recognized by
neonatal murine and human DC.
In conclusion, this is the first report that a novel subunit vaccine
against TB may elicit adult-like multifunctional and protective
CD4
+ T cell responses through the induction of an adult pattern of
in vivo DC activation in neonates. We cannot ensure that this will
be sufficient to confer adult-like protective capacity to this subunit
vaccine in human neonates. But this preclinical evaluation fully
supports including this novel vaccine among the most promising
novel infant TB vaccines.
Figure 4. Targeted functional activation of DC in neonates and adults. Twenty-four hours after immunization, (A) the expression of CD40,
CD80 and CD86 and (B) IL-12p40 by total DC and adjuvant
+ DC was assessed. Histograms represent the expression of co-stimulation molecules by
total DC in control mice (dotted line), total DC (thin lined histogram) and Ag85B-ESAT-6
+ IC31H
+ DC (thick lined histogram) in Ag85B-ESAT-6/IC31H-
immunized mice. Data is expressed as mean and SD of groups of at least 5 individual mice, and is representative of 2–3 independent experiments.
doi:10.1371/journal.pone.0003683.g004
Figure 5. Alum induces similar uptake of antigen, but a slight
activation of antigen
+ DC in adult compared to neonates.
Twenty-four hours after immunization, (A) the number of antigen
+ DC
and (B) the expression of CD40 and CD86 by total DC and antigen
+ DC
were assessed. The data are expressed as mean and SD of groups of at
least 5 individual mice, and is representative of 2 independent
experiments. *, p,0.05 signifies differences between neonates and
adult mice.
doi:10.1371/journal.pone.0003683.g005
Neonatal TB Vaccine Response
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Mice
Specific pathogen-free C57BL/6 mice (7 days of age (1-week-
old, neonates) or 8–12 weeks old (adult), Charles River) were bred
and kept under specific pathogen-free conditions in the university
zootechnology unit. Mice were immunized at the base of the neck
using the subcutaneous (s.c.) route. Mice received two (three weeks
apart) or one dose of the formulations for analysis of T cell
function and challenge studies. For analyses of in vivo DC
activation, the axial, brachial and auricular lymph nodes were
harvested 24 hours following a single immunization. Manipula-
tions were conducted according to Swiss and European guidelines
and experiments approved by the Geneva Veterinary Office.
Antigen, Adjuvants, TLR ligands and immunization
Recombinant Ag85B-ESAT-6 was prepared as described [28]
and coupled with fluorescein (Sigma, St. Louis, Mo.) or
AlexaFluor 647 (Invitrogen Basel, Switzerland). IC31H, consisting
of KLK (NH2-KLKL5KLK-COOH) and ODN1a (phosphodie-
ster backbone ODN, 59- ICI CIC ICI CIC ICI CIC ICI CIC IC-
39), including TAMRA-coupled KLK and Cy5-coupled ODN1a,
was produced as described [26]. Vaccines were formulated by
absorbing antigens (5 or 15 mg) with IC31H (100 nmol KLK/
4 nmol ODN1a) in 10 mM Tris–HCl/270 mM sorbitol buffer
(pH 7.5–8) or Al(OH)3 (Alum, gift of Chiron Vaccines). The adult
dose of Al(OH)3 (1 mg) was weight-adjusted to 0.25 mg for
immunization of 1-wk-old mice respectively, as previously
experimentally defined [22]. The buffer was used for control
immunization.
Determination of T cell responses
Three weeks after immunization (either second of two doses or a
single dose), splenocytes were cultured with Ag85B-ESAT-6
(5 mg/ml) or medium alone. For determination of cytokine by
ELISA or bioassay, supernatants collected after 72 h for
quantification by ELISA of IFN-c and IL-5 [17], TNF-a (BD
Biosciences, San Diego, CA), IL-17 (R&D Systems, Abingdon,
UK) and by bioassay IL-2 [44]. Under these conditions, blocking
studies with antibodies against CD4 (clone GK1.5) and CD8
(clone H35-17.2) were undertaken. The antigen-specific IFN-c-
secreting T cells were quantified by ELISPOT, using Ag85B-
ESAT-6 (2 mg/ml) or media alone for 48 h [45]. For determina-
tion of cytokine expression and multi-functional T cells by
intracellular staining (ICS), splenocytes were cultured with
Ag85B-ESAT-6 (5 mg/ml) or medium alone as well as anti-
CD28 and anti-CD49d antibodies (BD Pharmingen) for 1 hour,
before the addition of Brefeldin A and monensin (Sigma).
Following an additional 6 hour incubation, cells were stained
with conjugated antibodies against CD4 (clone GK1.5), CD8a
(clone 53-6.7) and CD44 (clone IM7) and then fixed and
permeabilized with BD Cytofix/cytoperm solution. Cells were
stained with conjugated antibodies against IFN-c (clone XMG1.2),
TNF-a (clone MP6-XT22), IL-2 (clone JES6-5H4) (BD Pharmin-
gen) and IL-17 (clone eBio17B7)(eBioscience, San Diego, CA).
Each sample was acquired on the FACSAria cytometer (BD
Figure 6. Ag85B-ESAT-6/IC31H protects neonates and adults from mycobacterial infection. Immunized neonatal and adult mice were
challenged with Mycobacterium bovis BCG i.v. The CFU in spleen (A) and lung (B) (mean6SD, n=6–8/group) were determined four weeks later, and is
representative of 2 independent experiments. *, p,0.05, differences between IC31H and Alum or control were significant.
doi:10.1371/journal.pone.0003683.g006
Neonatal TB Vaccine Response
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(Tree Star, Ashland, OR) and gating combination shown in
Figure 2.
Dendritic cell preparation, cell staining and flow
cytometry
CD11c
+ DC from draining LN, 24 hours after immunization,
were prepared by magnetic selection (Miltenyi Biotec, Bergisch-
Gladbach, Germany) as described [31]. Cells were pre-incubated
with rat anti-CD16/32 mAb (2.4G2 clone), then stained with
conjugated antibodies against CD11c (HL3 clone), CD80 (16-
10A1 clone), CD11b (M1/70 clone), CD8 (53-6.7 clone), isotype
controls (BD Pharmingen), CD86 (GL1 clone) (Biosource
International, Camarillo CA), CD11c (N418 clone), CD40
(FGK45 clone) (produced in house). Cells were further stained
with streptavidin-PE or streptavidin-PECy7 (BD Pharmingen).
Each sample was acquired on the FACSCalibur or FACSAria
cytometers and data were analyzed using the CellQuest Software
(BD Biosciences) or the FlowJo Software. Results were expressed
as the ratio of Mean Fluorescence intensity (MFI) compared to
controls in order to allow objective comparisons between
experiments. IL-12p40 was detected by ICS as described [31].
Mycobacterial challenge
Six weeks after the second immunization, mice were infected i.v
with 10
7 CFU of Mycobacterium bovis BCG Danish 1331. Four
weeks p.i., mice were sacrificed and spleens and lungs homoge-
nized for bacterial enumeration. Individual organs were plated in
serial dilutions onto Middlebrook 7H11 agar and incubated for
3 weeks at 37uC prior to counting the number of CFU.
Statistical analysis
Statistical analyses of the results obtained in various experi-
mental groups were performed with the Mann-Whitney U test
(two groups) or ANOVA with Tukey test (more than two groups).
Differences with probability values of .0.05 were considered
insignificant.
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